Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.
Højlund M, Köhler-Forsberg O, Gregersen AT, Rohde C, Mellentin AI, Anhøj SJ, Kemp AF, Fuglsang NB, Wiuff AC, Nissen L, Sørensen MA, Madsen NM, Wagner CB, Agharazi A, Søndergaard C, Sandmark M, Reinhart J, Correll CU. Højlund M, et al. Among authors: wagner cb. Lancet Psychiatry. 2024 Dec;11(12):975-989. doi: 10.1016/S2215-0366(24)00314-6. Epub 2024 Nov 12. Lancet Psychiatry. 2024. PMID: 39547246
Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias.
Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D. Wagner CB, et al. Leuk Lymphoma. 2024 Sep;65(9):1362-1365. doi: 10.1080/10428194.2024.2350670. Epub 2024 Jun 2. Leuk Lymphoma. 2024. PMID: 38824620 No abstract available.
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Afrough A, et al. Among authors: wagner cb. Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0. Blood Cancer J. 2024. PMID: 38609386 Free PMC article. No abstract available.
Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
Shinn LT, Benitez LL, Perissinotti AJ, Reid JH, Buhlinger KM, van Deventer H, Barth D, Wagner CB, Zacholski K, Desai R, Soule A, Stump SE, Weis TM, Bixby D, Burke P, Pettit K, Marini BL. Shinn LT, et al. Among authors: wagner cb. Int J Hematol. 2023 Dec;118(6):682-689. doi: 10.1007/s12185-023-03670-3. Epub 2023 Oct 26. Int J Hematol. 2023. PMID: 37882977
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Bowers JT, et al. Among authors: wagner cb. Blood Adv. 2023 Nov 14;7(21):6630-6638. doi: 10.1182/bloodadvances.2023010622. Blood Adv. 2023. PMID: 37595053 Free PMC article.
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: wagner cb. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia.
Lee JS, Wagner CB, Prelewicz S, Kurish HP, Walchack R, Cenin DA, Patel S, Lo M, Schlafer D, Li BKT, Donald Harvey Iii R, Wasef B, Ying J, Kovacsovics T. Lee JS, et al. Among authors: wagner cb. Haematologica. 2023 Dec 1;108(12):3460-3463. doi: 10.3324/haematol.2022.281967. Haematologica. 2023. PMID: 37345485 Free PMC article. No abstract available.
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.
Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H. Wagner CB, et al. Haematologica. 2023 Nov 1;108(11):3025-3032. doi: 10.3324/haematol.2023.282780. Haematologica. 2023. PMID: 37102592 Free PMC article.
RNA-DNA hybrids prevent resection at dysfunctional telomeres.
Pires VB, Lohner N, Wagner T, Wagner CB, Wilkens M, Hajikazemi M, Paeschke K, Butter F, Luke B. Pires VB, et al. Among authors: wagner cb. Cell Rep. 2023 Feb 28;42(2):112077. doi: 10.1016/j.celrep.2023.112077. Epub 2023 Feb 1. Cell Rep. 2023. PMID: 36729832 Free article.
15 results